Immediate Impact

1 by Nobel laureates 1 from Science/Nature 66 standout
Sub-graph 1 of 24

Citing Papers

Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
2023 Standout
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
2 intermediate papers

Works of E. Montegriffo being referenced

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
2012
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
2011

Author Peers

Author Last Decade Papers Cites
E. Montegriffo 33 94 23 148 140 6 267
W. Messersmith 5 95 32 203 87 9 298
R Canaletti 7 105 9 172 63 7 307
Victoria Kaestner 26 38 13 154 58 6 303
Jacques Cretin 18 44 5 167 85 9 324
Nikolas Tsavaris 7 33 7 191 125 11 323
Tomohiro Funakoshi 6 94 6 109 109 11 320
Charles L. Wiggins 21 120 7 194 64 12 318
Seon-Hee Yim 19 73 7 129 57 11 297
Matthew Boron 85 28 41 154 80 6 295
Tyler B. Kratzer 16 81 8 131 102 8 319

All Works

Loading papers...

Rankless by CCL
2026